Literature DB >> 10708958

TGF-betas and TGF-beta receptors in atherosclerosis.

T A McCaffrey1.   

Abstract

Based on diverse evidence in animals and humans, it has been hypothesized that atherosclerosis, and other injury-induced hyperplasias such as restenosis, may result from a failure in endogenous inhibitory systems that normally limit wound repair and induce regression of wound repair cells. A key defect in one of these inhibitory pathways, the TGF-beta system, has been identified and characterized in both animal models and in human lesions and lesion-derived cells. Cells derived from human lesions are resistant to the antiproliferative and apoptotic effects of TGF-beta, while their normal counterparts from the vascular media are potently inhibited and killed. Both cell types increase PAI-1 production, switch actin phenotypes in response to TGF-beta1, and produce similar levels of TGF-beta activity. Membrane cross-linking of (125)I-TGF-beta1 indicates that normal human SMC express Type I, II and III receptors. The Type II receptor is strikingly decreased in lesion cells, with little change in the Type I or III receptors. RT-PCR confirmed that the Type II TGF-beta1 receptor mRNA is reduced in lesion cells. Subsequent analysis of human lesion vs normal tissues confirmed that the Type I receptor was consistently present in the lesion, while the Type II receptor was much more variable, and commonly absent in both coronary artery and carotid artery lesions. Transfection of the Type II receptor into lesion cells partially restores the growth inhibitory response to TGF-beta1, implying that signaling remains intact. A subset of patients, and cells derived from their lesions, exhibit acquired mutations in the Type II receptor that would explain their resistance, though the majority of cells are resistant without obvious mutational defects. Thus, it is currently being tested whether transcriptional defects or abnormalities in receptor processing may explain the low levels of the Type II receptor. Because TGF-beta1 is overexpressed in fibroproliferative vascular lesions, receptor-negative cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708958     DOI: 10.1016/s1359-6101(99)00034-9

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  24 in total

1.  Long-term treatment with TGFbeta1 impairs mechanotransduction in bovine aortic endothelial cells.

Authors:  M Watanabe; M Oike; Y Ohta; Y Ito
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

2.  Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis.

Authors:  P Reisdorf; D A Lawrence; V Sivan; E Klising; M T Martin
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways.

Authors:  Joan C Smith; Braden E Boone; Susan R Opalenik; Scott M Williams; Shirley B Russell
Journal:  J Invest Dermatol       Date:  2007-11-08       Impact factor: 8.551

4.  Development of vascular smooth muscle contractility by endothelium-derived transforming growth factor β proteins.

Authors:  Chiwaka Kimura; Shuhei Konishi; Maki Hasegawa; Masahiro Oike
Journal:  Pflugers Arch       Date:  2013-07-26       Impact factor: 3.657

5.  Chronic treatment with C-type natriuretic peptide impacts differently in the aorta of normotensive and hypertensive rats.

Authors:  Carolina Caniffi; Flavia M Cerniello; Gonzalo Bouchet; María L Sueiro; Analía Tomat; Daniel González Maglio; Jorge E Toblli; Cristina Arranz
Journal:  Pflugers Arch       Date:  2019-06-11       Impact factor: 3.657

6.  Sustained contraction and loss of NO production in TGFbeta1-treated endothelial cells.

Authors:  M Watanabe; M Oike; Y Ohta; H Nawata; Y Ito
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

7.  Coding Microsatellite Frameshift Mutations Accumulate in Atherosclerotic Carotid Artery Lesions: Evaluation of 26 Cases and Literature Review.

Authors:  Carolin Kurz; Maani Hakimi; Matthias Kloor; Caspar Grond-Ginsbach; Marie-Luise Gross-Weissmann; Dittmar Böckler; Magnus von Knebel Doeberitz; Susanne Dihlmann
Journal:  Mol Med       Date:  2015-06-09       Impact factor: 6.354

8.  Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries.

Authors:  Ick-Mo Chung; Junwoo Kim; Youngmi K Pak; Yangsoo Jang; Woo-Ick Yang; Innoc Han; Seung-Jung Park; Seong-Wook Park; Jooryung Huh; Thomas N Wight; Hikaru Ueno
Journal:  Int J Cardiol       Date:  2010-01-06       Impact factor: 4.164

9.  Ascending thoracic aortic aneurysms protect against myocardial infarctions.

Authors:  Katherine Chau; John A Elefteriades
Journal:  Int J Angiol       Date:  2014-09

10.  Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis.

Authors:  Ashwani K Khanna
Journal:  J Biomed Sci       Date:  2009-07-15       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.